Ekaterina Klykova is a Master's student in Health Economics at the Université de Reims Champagne-Ardenne, France. She holds a degree in International Relations from MGIMO University in Moscow, where she specialised in Latin America. Her research interests include comparative health policy, access to medicines, and the influence of geopolitics and international institutions on health systems and pharmaceutical regulation. 

Abstract:
Adverse drug reactions cause an estimated 197,000 deaths annually in Europe and cost healthcare systems billions. Pharmacovigilance, the system responsible for monitoring drug safety after medicines reach the market, remains largely reactive: it identifies most problems only after harm has occurred. Integrating telemonitoring and artificial intelligence offers a way to change this. The combination has already demonstrated clinical value in detecting adverse drug reactions earlier than conventional pharmacovigilance methods. Yet widespread adoption remains absent even in European countries with advanced digital infrastructure. This study looks at why the gap between proof and practice persists, and what it reveals about how pharmaceutical safety actually works in Europe.